血管内皮抑制素恩度的药理分析与肝癌治疗的临床评价  

Pharmacological analysis of endostatin endostar and its clinical evaluation in liver cancer treatment

作　　者：李竹岩[1] 

机构地区：[1]山东省邹城市人民医院药剂科,273500

出　　处：《中国现代药物应用》2015年第10期3-5,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨血管内皮抑制素恩度的药理作用,观察恩度治疗肝癌的临床疗效。方法选取原发性肝细胞癌(简称肝癌)患者60例,按照随机对照法分为观察组和对照组,各30例,其中观察组给予肝动脉化疗栓塞术(TACE)联合重组人血管内皮抑制素注射液(恩度)治疗,对照组采用单纯的TACE治疗,观察两组患者治疗前、治疗后1、3、7、15、30 d血清血管内皮生长因子(VEGF)、基质金属蛋白酶9(MMP-9)、骨桥蛋白(OPN)水平的变化。结果治疗前两组的血清VEGF、MMP-9、OPN水平比较,差异无统计学意义(P>0.05);治疗后各时间节点观察组血清VEGF、MMP-9、OPN水平与治疗前比较,差异无统计学意义(P>0.05);而对照组治疗后各时间节点血清VEGF、MMP-9、OPN水平均较治疗前明显升高,差异具有统计学意义(P<0.05)。结论血管内皮抑制素恩度治疗肝癌可以有效抑制肿瘤新生血管的形成,降低肿瘤复发转移的几率,延长患者的生存时间,提高生存率,其作用机制可能与抑制TACE术后血浆VEGF、MMP-9、OPN水平有关。Objective To investigate the pharmacological effect of endostatin endostar, and to observe its clinical effect in liver cancer treatment. Methods A total of 60 primary hepatocellular carcinoma （liver cancer） patients were randomly divided into observation group and control group, with 30 cases in each group. The observation group received transcatheter arterial chemoembolization （TACE） combined with endostatin injection （endostar） for treatment, and the control group received TACE treatment alone. Changes of serum vascular endothelial growth factor （VEGF）, matrix metalloproteinase 9 （MMP-9）, and osteopontin （OPN） levels were observed before treatment and after 1, 3, 5, 7, 15, 30 d of treatment in the two groups. Results The difference of serum VEGF, MMP-9, and OPN before treatment between the two groups had no statistical significance （P〉0.05）. After treatment, the levels of VEGF, MMP-9, and OPN at each time points had no statistically significant difference with those before treatment （P〉0.05）. The control group had much higher levels of VEGF, MMP-9, and OPN at each time points after treatment than those before treatment, and the difference had statistical significance （P〈0.05）. Conclusion Endostatin endostar in treating liver cancer can effectively suppress tumor angiogenesis, reduce relapse and metastasis rates, lengthen survival time, and improve survival rate. Its mechanism may berelated with suppression of serum VEGF, MMP-9, and OPN levels after TACE.

关 键 词：血管内皮抑制素 血管内皮生长因子 基质金属蛋白酶9 骨桥蛋白 

分 类 号：R735.7[医药卫生—肿瘤]